Albert M. Kim

发表

Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome

Jeffrey R. Chabot, A. Kalgutkar, L. Buckbinder, 2017, Drug Metabolism and Disposition.

New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk

Jennifer G. Robinson, G. De Backer, C. Shear, 2018, European heart journal. Cardiovascular pharmacotherapy.

Lipid‐Reduction Variability and Antidrug‐Antibody Formation with Bococizumab

P. Ridker, R. Glynn, J. Kastelein, 2017, The New England journal of medicine.

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

M. Inglot, T. Tuthill, J. Pfefferkorn, 2021, Nature Medicine.

Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency

Jeroen J. Bax, G. Hindricks, D. Atar, 2016, European journal of heart failure.

New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment

P. Ponikowski, B. Tyl, M. Pfeffer, 2017, European journal of heart failure.

Once‐weekly administration of a long‐acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non‐human primates

Jeffrey R. Chabot, T. Rolph, Y. Weng, 2017, Diabetes, obesity & metabolism.

Once-weekly administration of a long-acting FGF 21 analogue modulates lipids , bone turnover markers , blood pressure , and body weight differently in obese hypertriglyceridemic subjects and in non-human primates

Jeffrey R. Chabot, T. Rolph, Y. Weng, 2017 .

Mixed meal tolerance testing highlights in diabetes altered branched-chain ketoacid metabolism and pathways associated with all-cause mortality.

R. Gerszten, A. Bertoni, L. Farrell, 2023, The American journal of clinical nutrition.

Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial

Donal N. Gorman, A. Bergman, Donal N Gorman, 2021, Nature Medicine.

Myeloperoxidase inhibition in mice alters atherosclerotic lesion composition

A. Kalgutkar, L. Buckbinder, E. Keliher, 2019, PloS one.

Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis

B. Goodwin, Tong Zhu, S. Carvajal-Gonzalez, 2019, Science Translational Medicine.

Erratum to “Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency” [Eur J Heart Fail 2016;18:482‐489]

Jeroen J. Bax, G. Hindricks, D. Atar, 2016, European journal of heart failure.

A phase 2a, randomized, double‐blind, placebo‐controlled, three‐arm, parallel‐group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF‐06835919 in patients with non‐alcoholic fatty liver disease and type 2 diabetes

M. Whitlock, W. Esler, K. Khavandi, 2022, Diabetes, obesity & metabolism.

Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co‐mixture with recombinant human hyaluronidase: A phase 1 randomized trial

Almasa Bass, A. Płotka, D. Plowchalk, 2018, Health science reports.